2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2552

Predictive Value of Chest HRCT Patterns for Respiratory Adverse Event Among RA Patients Treated with Biological Therapy: Long-Term Results from an Observational Study
Abstract Number: 1720

Predictive Value of Different Tools for Detection of Psoriatic Arthritis in Patients with Psoriasis in Daily Routine Care Using Questionnaires for Diagnosis of Psoriatic Arthritis and Fluorescence-Optical Imaging Technique
Abstract Number: 2402

Predictive Value of the History and Labs in Distinguishing Inflammatory from Non-Inflammatory and Mechanical Joint Pain
Abstract Number: 1818

Predictors for Mortality in Hospitalized Patients with Systemic Lupus Erythematosus from 1999 to 2009: A Follow-up Multicenter Study in China
Abstract Number: 1722

Predictors of Achieving Remission Among Patients with Psoriatic Arthritis Prescribed TNF Inhibitors
Abstract Number: 1889

Predictors of Acro-Osteolysis in Systemic Sclerosis
Abstract Number: 2233

Predictors of Adherence and Costs in First and Second Years after Biologic Initiation in Patients with Rheumatoid Arthritis (RA)
Abstract Number: 1374

Predictors of Changes in Disease Activity Among Children with Juvenile Dermatomyositis
Abstract Number: 398

Predictors of Clinical Remission with Etanercept in Pediatric Patients with Extended Oligoarticular, Enthesitis-Related Arthritis and Psoriatic Arthritis: Findings from the Clipper Study
Abstract Number: 750

Predictors of Corticosteroid Use in the Systemic Lupus International Collaborating Clinics Inception Cohort – a Multivariate Analysis
Abstract Number: 1971

Predictors of Delays to Care and Associated Outcomes in Pediatric Lupus Patients from the Childhood Arthritis and Rheumatology Research Alliance Registry
Abstract Number: 2519

Predictors of Flare in Rheumatoid Arthritis Patients Treated Preventively with Rituximab: A Prospective Study Using Ultrasound and Patient Reported Outcomes
Abstract Number: 334

Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Abstract Number: 2842

Predictors of Good Long-Term Renal Outcomes in Lupus Nephritis
Abstract Number: 525

Predictors of Health Care Drop-out in an Inception Cohort of Patients with Early Onset Rheumatoid Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].